Sanofi Return on Investment 2010-2023 | SNY
Current and historical return on investment (ROI) values for Sanofi (SNY) over the last 10 years.
| Sanofi ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2023-12-31 |
$9.59B |
$96.00B |
20.08% |
| 2023-09-30 |
$10.30B |
|
21.70% |
| 2023-06-30 |
$11.11B |
$95.07B |
23.40% |
| 2023-03-31 |
$10.71B |
|
22.82% |
| 2022-12-31 |
$10.72B |
$94.83B |
22.85% |
| 2022-09-30 |
$12.21B |
|
52.62% |
| 2022-03-31 |
$8.80B |
|
35.93% |
| 2021-09-30 |
$9.03B |
|
36.89% |
| 2021-03-31 |
$10.31B |
|
inf% |
| 2020-09-30 |
$9.32B |
|
inf% |
| 2020-03-31 |
$7.94B |
|
inf% |
| 2019-09-30 |
$6.79B |
|
33.11% |
| 2019-03-31 |
$6.71B |
|
32.71% |
| 2018-03-31 |
$6.77B |
|
16.67% |
| 2017-12-31 |
$7.07B |
$82.04B |
17.42% |
| 2017-09-30 |
$7.72B |
|
18.98% |
| 2017-06-30 |
$8.01B |
$80.29B |
19.69% |
| 2017-03-31 |
$8.14B |
|
20.27% |
| 2016-12-31 |
$7.59B |
$82.49B |
18.91% |
| 2016-09-30 |
$8.06B |
|
41.24% |
| 2016-06-30 |
$7.47B |
$78.17B |
19.54% |
| 2016-03-31 |
$7.72B |
|
19.35% |
| 2015-09-30 |
$7.96B |
|
12.90% |
| 2015-06-30 |
$7.84B |
$74.72B |
9.42% |
| 2014-06-30 |
$8.29B |
$84.89B |
12.86% |
| 2013-06-30 |
$8.36B |
$87.34B |
12.43% |
| 2012-06-30 |
$9.00B |
$85.62B |
19.82% |
| 2012-03-31 |
$8.41B |
|
17.63% |
| 2011-12-31 |
$8.89B |
$95.95B |
18.64% |
| 2011-09-30 |
$8.20B |
|
18.80% |
| 2011-06-30 |
$8.97B |
$94.81B |
20.57% |
| 2011-03-31 |
$10.32B |
|
26.49% |
| 2010-12-31 |
$9.22B |
$79.65B |
23.67% |
| 2010-09-30 |
$8.91B |
|
23.46% |
| 2010-06-30 |
$8.83B |
$76.10B |
23.25% |
| 2010-03-31 |
$8.80B |
|
24.05% |
| 2009-12-31 |
$8.81B |
$75.88B |
24.08% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$122.484B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
